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Introduction 
“The physician sets about his task with healthy mind and healthy body…[and] the patient 
knows neither what he is suffering from, nor the cause….[nor] the outcome of his present 
state…. Surely it is much more likely that the physician gives proper orders, which the 
patient not unnaturally is unable to follow.” 
-Hippocrates, “The Art,” c. 5th century BCE 
 
Diabetes mellitus (diabetes) is a highly prevalent metabolic disorder that afflicts 
9.3% of the US population (29.1 million people)1, and 382 million people worldwide.2 In 
2012, diabetes was responsible for 1.5 million deaths worldwide, making it the 8th 
leading cause of death in the world.3 This figure has increased since 2000, when diabetes 
was responsible for 1 million deaths.3 Untreated or inadequately treated diabetes leads to 
chronic high blood glucose (hyperglycemia), which can cause many adverse effects, 
including intensified thirst, frequent urination and fatigue. Much more concerning are the 
potential long term complications such as blindness, peripheral nerve damage, kidney 
damage, large blood vessel disease, and limb loss. Diabetes accounts for 44% of all new 
cases of kidney failure and increases the risk of heart disease death and stroke by 2-4 fold 
in adults.1 Additionally, 60% of people 20 years and older who need non-traumatic 
lower-limb amputations also have diabetes.1 Individuals with Type 2 diabetes have a 
decreased life expectancy relative to non-diabetic individuals with similar 
characteristics.4 In 2012, the ADA estimated that diabetes care cost the U.S. $245 billion, 
$176 billion of which was from medical expenditures and $69 billion from reduced 
productivity.5 The same report stated that on average, individuals with diabetes incur 2.3 
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times more yearly medical expenses than individuals without diabetes.5 In light of these 
facts, it is clear that reducing the morbidity and mortality burden from diabetes is an 
important public health issue. 
Endocrinologists generally recognize three main types of diabetes: Type 1 
diabetes, Type 2 diabetes, and gestational diabetes. All three types of diabetes are 
disorders of metabolism due to disturbances in the function of the hormone insulin. 
Insulin activates cellular glucose uptake and increased glucose metabolism. It works 
antagonistically with the hormone glucagon to regulate blood glucose levels. All three 
types of diabetes are characterized by the inability of cells to take up glucose from the 
blood, either due to a deficiency of insulin or insensitivity to its effects. Type 1 diabetes 
is an autoimmune disorder in which the beta cells (insulin-producing cells) of the 
pancreas are targeted for destruction by the immune system, leading to a systemic insulin 
deficiency. Type 1 diabetes comprises only 5-10% of all diabetes cases1, and is thought to 
result from a combination of environmental and genetic factors. Type 1 diabetes is 
typically diagnosed in children and young adults. Gestational diabetes is a temporary 
condition experienced by about 18% of pregnant mothers, usually beginning during the 
third trimester and resolving after delivery.6 Although gestational diabetes is temporary, 
mothers with gestational diabetes have an increased future risk for developing Type 2 
diabetes. Type 2 diabetes occurs when cells acquire resistance to insulin, which often 
leads to a halt in insulin production by the pancreatic beta cells. Type 2 diabetes accounts 
for 90-95% of diabetes cases1 and has a genetic- and lifestyle-based etiology. Obesity, 
poor nutrition, lack of exercise, old age and stress are each associated with the 
development of Type 2 diabetes. In addition, the onset of Type 2 diabetes occurs much 
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more gradually than that of Type 1 diabetes, which has an acute onset marked by a 
characteristically rapid increase in blood glucose.7 The focus of this thesis will be on 
Type 2 diabetes. 
 Diabetes is most frequently diagnosed by testing for elevated blood glucose. 
There are several different blood glucose tests; fasting plasma glucose (FPG) focuses 
upon the plasma glucose level after a 12-14 hour fast. A more detailed characterization of 
blood glucose is achieved via the oral glucose tolerance test (OGTT), in which a standard 
dose of glucose is administered and blood glucose is measured at baseline and at 30 
minute intervals until 2 hours later, which tests the body’s ability to clear glucose from 
the blood. Finally, the percentage of glycosylated hemoglobin (HbA1c) summarizes 
average blood glucose concentration over a period of 2-3 months. In 2006, the World 
Health Organization (W.H.O.) defined diabetes as having either FPG ≥ 7.0 mmol/l and/or 
OGTT ≥ 11.1 mmol/l with diabetes symptoms.8 In 2009, diabetes was redefined as 
having HbA1c ≥ 6.5%, which is much more practical in that patients do not have to 
undergo a fasting or lengthy test. These definitions apply to both Type 1 and Type 2 
diabetes.8 
Treatment of Type 2 diabetes requires individuals to be very involved in their 
own chronic illness self-management. Generally, initial Type 2 diabetes treatments utilize 
diet and exercise to lower blood glucose. If executed properly, diet and exercise alone can 
often return the body to a normoglycemic state and prevent the progression of diabetes. 
The ADA recommends that individuals with Type 2 diabetes derive most or all of their 
dietary carbohydrates from whole grains, legumes, fruits and vegetables.9 The same 
report also recommends limiting saturated fat intake to less than 7% of total daily 
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calories, limiting salt intake, and eating fish two times per week. When diet and exercise 
recommendations alone fail to effectively reduce blood glucose levels, then typically Oral 
Hypoglycemic Agents (OHAs) are prescribed. OHAs are drugs that lower blood glucose 
through various mechanisms. For example, biguanides (e.g. metformin), increase the 
liver’s ability to respond to insulin; α-glucosidase inhibitors (e.g. acarbose, miglitol) 
decreases glucose absorption in the small intestine; sulfonylurea derivatives (e.g. 
glyburide, glimepride) increase insulin release from the pancreas. If OHAs fail to 
effectively manage blood glucose, then patients are typically prescribed exogenous 
insulin. Self-injected or inhaled insulin is always required to treat Type 1 diabetes and is 
used to treat individuals with poorly controlled Type 2 in combination with OHAs.10 
Individuals using insulin need to frequently self-monitor their blood glucose levels, using 
a portable personal device known as a glucometer, in order to determine the appropriate 
insulin dose needed for their current blood glucose and anticipated carbohydrate 
intake/expenditure. In addition, physicians also usually recommend that people with 
diabetes regularly monitor themselves for certain symptoms of long-term complications. 
For example, diabetes can lead to nerve and blood vessel damage in the feet, so it is 
important that diabetes patients check their feet daily for tissue damage to help prevent 
the development of non-healing ulcers. Finally, because diabetes can lead to blindness by 
decreasing blood supply to the retina, the ADA recommends that diabetes patients see an 
ophthalmologist for annual dilated eye examinations.11  
 While Type 2 diabetes (hereinafter referred to as “diabetes”) takes a large toll on 
the entire population, there are significant racial disparities in diabetes outcomes and 
diabetes care. In 2011, diabetes was 1.7 times more prevalent among African Americans 
5 
than Caucasian Americans.12 In addition to the disproportionately high prevalence of 
diabetes among African Americans, African Americans were also 2.2 times as likely to 
die from diabetes as Caucasian Americans in 2010.13 African Americans with diabetes 
also experience an increased rate of diabetic retinopathy14, are about 4 times more likely 
to develop kidney disease15, and have on average 1.7 fewer quality-adjusted life-years 
(QALYS) than Caucasian Americans with diabetes.16 It is thought that this disparity 
stems from a variety of societal, cultural and biological factors. 
Several efforts have been made to specifically improve diabetes care for African 
Americans. In a 2012 review article17, Betancourt et al. described three types of relatively 
successful recent efforts: 1) community-based efforts, which involve fellow community 
members, both with and without diabetes, take an active role in helping patients 
understand diabetes care and set goals for diabetes self-management; 2) distributing 
health information technology, such as personal electronic devices as a means to 
communicate with patients about their diabetes care; 3) multifaceted, systemic 
interventions that make diabetes education more culturally appropriate and/or improve 
the cultural awareness of physicians treating African American patients. Each of these 
efforts have been tested in multiple studies and have been shown to be effective in 
reducing HbA1c of African Americans with poorly controlled Type 2 diabetes.17  
 In spite of these efforts, vast disparities in diabetes treatment outcomes remain. 
Therefore, a fresh perspective on the causes of these disparities could help policy makers 
and health care providers develop better interventions or rework existing interventions to 
help eliminate these disparities. Several hypotheses have been proposed to explain this 
inequity. One hypothesis is that African Americans have certain genetic factors that lead 
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to a predisposition to insulin resistance or obesity. Additionally, most peer-reviewed 
research on the efficacy of different diabetes medications studies a disproportionately 
high number of Caucasian populations, and therefore may not generalize well to African 
Americans. Because of this, it is also possible that unidentified, genetically based 
differences in the way African Americans respond to certain OHAs could be contributing 
to poor diabetes control among African Americans.18 Genetic factors have also been 
theorized to contribute to the increased risk of diabetes-related complications in African 
Americans.15 
Differences in obesity, income and education levels could also possibly explain 
the disparity in diabetes outcomes. Obesity is one of the strongest risk factors for the 
development of Type 2 diabetes, along with many other conditions. African American 
cultural dietary practices, particularly in the southern regions of the US and among lower 
SES individuals, commonly consist of high fat, high carbohydrate meals, which can lead 
to obesity.19 In the U.S., the age-adjusted obesity rate among African Americans is 
47.8%, compared to 32.6% among non-Hispanic whites.20 Additionally, in 2012, the U.S. 
Census reported that the average annual income for African Americans was $33,321, 
almost half of the average annual income for non-Hispanic whites ($57,009).21 In 2012, 
the percentage of individuals without health insurance was 24.9% for annual household 
incomes of less than $25,000, compared to only 7.9% for annual household incomes over 
$75,000.21 Moreover, a lack of financial resources can limit access to healthy food and 
places to exercise.22 The ethnic disparities in income and obesity in part explain the 
disparity in diabetes outcomes and care quality. 
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However, even after accounting for factors like health care access, socioeconomic 
status and obesity, African Americans are still found to have poorer diabetes control and 
to receive poorer quality diabetes care than Caucasian Americans.23 This could mean that 
something about the experience of being an African American unrelated to eating habits 
or health care access is associated with poor diabetes control. One concerning but 
plausible possibility is that African Americans receive worse quality diabetes care due to 
discrimination in clinical settings by providers. African Americans with diabetes are less 
likely to have HbA1c measurements, lipid testing or eye appointments than white patients 
with the same health care access.18 Similarly, African Americans are less likely to get flu 
and pneumonia vaccines from their primary care physicians than white patients.15 African 
American patients are also 1.7 times as likely to have ER visits that result in discharge 
without seeing a physician.24 Racial biases are manifest in the choices physicians make 
about their African American patients and the poor communication between physicians 
and African American patients. This may explain why African Americans have lower 
adherence to diabetes medications, dietary and exercise recommendations, and other self-
management behaviors like self-monitoring of blood glucose, which leads to poorer 
glycemic control, higher incidence of diabetes, and increased diabetes-related 
complications. This hypothesis, along with the genetic theories, may explain the 
additional risk associated with being African American that is unexplained by SES, 
obesity and health care access. 
This thesis will attempt to examine two of the theories described above about 
ethnic disparities in diabetes outcomes, along with a novel, third theory which will be 
discussed in detail below. These are that: 1) Poor patient education and poor 
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communication between health care providers and African American patients leads to 
decreased adherence to recommended diabetes self-management behaviors, 2) Obesity, 
physical inactivity, and high fat, high carbohydrate diets are more common among 
African Americans and are all associated with increased rates of Type 2 diabetes, and 3) 
Empowerment, or the personal sense of self-efficacy and internal locus of control over 
one’s diabetes, is lower in African American individuals, which could lead to poorer 
diabetes self-management. The topic of medication adherence and the concept of patient 
empowerment as they relate to ethnic disparities in diabetes outcomes will be discussed 
further below. 
 
Adherence 
To repeat the opening sentiment expressed by Hippocrates in “The Art”: 
“The physician sets about his task with healthy mind and healthy body…[and] the 
patient knows neither what he is suffering from, nor the cause….[nor] the 
outcome of his present state…. Surely it is much more likely that the physician 
gives proper orders, which the patient not unnaturally is unable to follow.” 
 
This quote describes central philosophies about the necessity of medicine and the process 
of diagnosing and treating patients. Even 2500 years ago, poor patient adherence limited 
the effectiveness of a physician’s recommendations. More surprising than that, however, 
is the idea that patients and healers hold a joint responsibility to find a treatment plan that 
is both effective and feasible. It was not until the 1980s that this idea resurfaced again in 
public health literature.25,26 Consider how far our knowledge of physiology and pathology 
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has improved since ancient Greece, where it was common to prescribe the ingestion of 
heavy metals or poisonous herbs for various diseases; on the other hand, our view of the 
role of patient adherence in medicine doesn’t seem to have progressed much since 
Hippocrates’ time. 
Patient adherence was defined by the W.H.O. in 2003 as “the extent to which a 
person’s behavior – taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with the agreed recommendations from a health care provider”27. 
This definition emphasizes the patient’s active role in their self care and takes into 
account the long-term self care required for chronic conditions like diabetes, congestive 
heart failure and HIV/AIDS, as opposed to acute conditions. “Adherence” has replaced 
“compliance” as the preferred terminology because “adherence” emphasizes dialogue 
between patient and provider, whereas compliance connotes the lack of a choice and/or 
involvement in following a health care provider’s recommendations.  
Adherence has been studied as a function of various regimens, interventions, and 
diseases since the 1950’s. It is estimated that overall treatment adherence for chronic 
conditions averages around 60%.28 Because it is associated with the development of 
costly complications and reduced productivity, nonadherence is estimated to cost 
upwards of $100 billion each year in the U.S.28 Nonadherence is often viewed in an 
overly simplistic manner as resulting from a lack in the self-discipline, will power or 
concern of the patient. However, others suggest that nonadherence is a deliberate, rational 
choice related to the patient’s goals and quality of life, while others point out the 
possibility of a fairly passive process, such as “forgetting.” Nevertheless, even if a patient 
autonomously decides to reject the recommendation of a health care provider for rational 
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reasons, preventable costs may still be incurred in the form of intensified medical care 
and reduced work productivity due to the development of otherwise preventable 
complications.29 Poor medication adherence contributes to many complications in 
patients with chronic heart failure and can lead to a pattern of recurring hospital 
admissions28 and ultimately death in some cases. 
Adherence to recommended diabetes medication regimens is highly important for 
maintaining good glycemic control. The first recommended measure to prevent diabetes 
progression and onset is to develop healthy eating habits and increase physical activity. 
As described above, OHAs are prescribed when diet and exercise are not sufficient to 
manage high blood sugar, which can often be a result of poor adherence to provider’s 
recommendations about diet and exercise. OHA nonadherence in Type 2 diabetes leads to 
poor glycemic control, and if nonadherence is not recognized as the reason, self-injected 
insulin is often prescribed. Nonadherence to either treatment often leads to 
hospitalizations and other serious complications caused by hyperglycemia. Thus, poor 
adherence to diabetes treatment regimens is a large determinant of future treatment 
outcomes.  
The literature remains unclear about whether or not ethnic disparities exist for 
adherence to diabetes treatment regimens and whether they are significant enough to 
explain disparities in glycemic control. A study by Adams et al. (2008) reported that 
while African Americans in their population of study had significantly lower OHA 
adherence than non-Hispanic whites (72% vs. 78%), accounting for this disparity in 
medication adherence was not sufficient to explain higher HbA1c levels among African 
Americans.30 However, in 2004, Pladevall et al. found that African American ethnicity 
11 
was no longer a significant predictor of HbA1c when metformin adherence was 
accounted for.31 Another study by Martin et al. (1995) found no significant ethnic 
differences in adherence to diabetes management behaviors.32 Egede and Dagogo-Jack 
also reported that there were no ethnic differences in adherence to diabetes self-
management behaviors, with the exception of the practice of monitoring one’s own blood 
glucose, for which African Americans had a 12% lower rate of adherence than Hispanic 
and white patients.15 In summary, there have been several conflicting results across 
studies as to whether a racial gap in diabetes self-management behavior adherence exists 
and whether it explains the ethnic disparity in glycemic control.  
One explanation for poor diabetes medication adherence is poor patient-provider 
communication.33 It is important for physicians and other health care providers to assess 
their patients’ comprehension of diabetes care information and treatment regimens33, and 
also to ask about medication adherence in a non-judgmental manner.34 Negatively 
phrased or leading questions about patients’ medication adherence might induce feelings 
of shame within patients34, thus making it difficult for providers to detect non-adherence 
and work to improve it. Racial concordance (whether the racial identity of the patient 
aligns with that of the provider) is an important factor in patient-provider communication, 
which can in turn have an influence on medication adherence. A study by Schoenthaler et 
al. (2012) examined the relationships between racial concordance, communication 
quality and medication adherence with a population of female, African American patients 
with hypertension.35 This group found that non-collaborative communication with a 
Caucasian physician had significant negative impacts on medication adherence, while 
poor communication with an African American physician had no impact on subsequent 
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medication adherence.35 Several other studies have provided evidence that a racially 
concordant interaction can benefit medication adherence among African Americans35. 
Since the number of Caucasian physicians greatly overwhelms the number of black 
physicians in the US36, this represents an additional barrier to African Americans in 
adhering to treatment regimens. 
 
Diet and Exercise 
 As stated above, obesity is highly associated with poor glycemic control and the 
onset of Type 2 diabetes, and obesity rates in the African American population are higher 
than that of the Caucasian population. A brief discussion about the various factors that 
influence obesity and how they may differentially affect African Americans will be 
provided in this section.  
Obesity is largely a product of dietary habits, physical activity levels, genetics, 
and age.37 Other factors like smoking and certain prescription medications may also 
affect macronutrient metabolism and lead to weight gain.37 Gender, income, education, 
and race are highly predictive of obesity rates within populations. Among Caucasian 
men, income levels are not related to obesity rates, but among African Americans and 
Mexican Americans, increasing income levels are associated with increasing obesity 
rates.38,39 Interestingly, these trends are almost exactly reversed for women, with 
increasing income levels being associated with decreasing obesity rates among Caucasian 
women and no relationship existing between income and obesity levels among African 
American and Mexican American women.38,39 Men and women of all races with college 
degrees have decreased obesity rates, but few trends exist for different education levels 
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below that of a college graduate.38 In 2014, 22.2% of African Americans in the U.S. had 
a college degree, compared to 32.3% for Caucasian Americans.40 This disparity in 
educational attainment may in part explain the overall increased obesity rates for African 
Americans. The factors that determine an individual’s ability to manage their weight 
(genetics, age, diet, physical activity, smoking, etc.) may be related to the interactions 
between race, gender and income levels. The reasons for which these trends in obesity 
exist are beyond the scope of this thesis, but nevertheless serve to illustrate the point that 
race and socioeconomic status interact to influence obesity rates, which in turn 
contributes to the increased prevalence of diabetes in the African American population.  
Additionally, African American culture surrounding food and eating habits also 
can negatively impact their diet. A study by Airhihenbuwa et al. examined attitudes 
towards African American cultural food practices among a population of African 
Americans in an urban community in Pennsylvania. The study found that many African 
Americans identify with the practice of eating “soul foods” like macaroni, grits, biscuits, 
fried chicken, chitlins, fat-back, ham hocks, fried okra, home fries, and more.41 
Interviewees attributed the development and maintenance of these practices in part to the 
influences of slavery, racial discrimination and socioeconomic status. While some of 
these foods, particularly the vegetables, are very micronutrient rich, fried foods and fatty 
meats are also high in fat, cholesterol and sodium. These dietary practices may contribute 
to the increased obesity rates in African Americans. It is thought that interventions 
directed at improving the dietary habits of African American ought to take these cultural 
practices into account. 
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Empowerment Theory 
A promising new perspective for analyzing racial disparities in medication 
adherence and diabetes outcomes is provided by the theory of “patient empowerment,” 
which was proposed by Anderson and Funnel. Anderson & Funnell (2000) advocate a 
self-empowerment-based model for diabetes care42, in which patients develop a 
personalized plan based upon their own priorities and goals for their diabetes 
management, rather than providers exhorting patients to more closely adhere to their 
recommendations, which may or may not align with the patient’s lifestyle and personal 
goals. The extent to which a patient has increased their self-efficacy and control over 
their own diabetes management relative to their goals can be measured by the Diabetes 
Empowerment Scale (DES).42 This new viewpoint represents a paradigm shift in diabetes 
care, in which the focus on compliance with physicians’ recommendation has been 
replaced with a focus on empowering patients to manage their own diabetes according to 
their own values and lifestyle.43 The present project was especially focused on 
understanding how this new approach affects African American patients with diabetes.  
Little research has been done on the effectiveness of empowerment-based 
diabetes care on African Americans specifically and on the extent to which African 
Americans are already empowered compared with Caucasian Americans (based on the 
DES). Anderson et al. (2005) performed a randomized control trial to examine the 
effectiveness of empowerment-based diabetes self-management education programs and 
found that the programs were able to significantly improve DES score and glycemic 
control.44 Another study by Steinhardt et al. (2010) tested a similar intervention, called 
the “Diabetes Coaching Program,” that was tailored for African Americans.45 This study 
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also found significant improvements in DES score and glycemic control. The results of 
these studies suggest that empowerment-based interventions are effective in improving 
African Americans’ diabetes care.  
Although the efforts aimed at empowering African American patients with 
diabetes have been successful, it remains unclear as to whether there is an underlying 
ethnically based disparity in diabetes-specific empowerment. A study by Sarkar et al. 
(2006) found that self-efficacy did not significantly differ between African Americans 
and Caucasian Americans46, although they used an alternative diabetes self-efficacy 
scale, rather than Anderson’s DES. Wallston et al. (2007) used the Perceived Diabetes 
Self-Management Scale (PDSMS), another measure of how competent and prepared 
patients feel to manage their diabetes, and found that Caucasian Americans had baseline 
scores equal to that of African American patients with diabetes.47 However, there have 
been no reports of baseline DES scores stratified by race, which makes it difficult to 
determine whether this factor is important in the ethnic disparity in diabetes outcomes. In 
this study, baseline DES scores will be compared between Caucasian Americans and 
African Americans in order to shed more light on the causes of these disparities. 
 
Treatment Regimen and Comorbidities 
An additional question that will be explored in this thesis is the relationship of 
treatment regimen and comorbidities with glycemic control, specifically whether the 
relationship differs by race. As mentioned previously, exogenous insulin is prescribed to 
individuals with Type 1 diabetes or poorly controlled Type 2 diabetes. Moreover, poorly 
controlled diabetes can lead to the development of various complications, which increase 
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the overall burden on these patients. Chronic hyperglycemia can lead to vascular, retinal 
and peripheral nerve damage, which may affect the ability of individuals with diabetes to 
exercise, take medications or perform other diabetes self-management behaviors. 
Additionally, individuals with diabetes often have several other preexisting conditions 
that did not result from their diabetes, such as depression, asthma, cardiovascular disease, 
obesity, and chronic obstructive pulmonary disease (COPD), which can also create 
difficulties in the management of diabetes.48 Because African Americans have more 
poorly controlled diabetes than Caucasian Americans, one might expect that treatment 
with exogenous insulin and a high number of comorbid conditions are more common 
among African Americans. Thus, it is possible that the ethnic disparity in diabetes 
management in part stems from both an increased prevalence of preexisting 
comorbidities and a reduced ability to self-manage diabetes care alongside these 
conditions among African Americans. Similarly, it is also possible that African 
Americans and Caucasian Americans do not respond the same way to treatment with 
exogenous insulin. This thesis will test these hypotheses, although the lack of 
longitudinal data places a limit on our ability to fully understand how the time course of 
the development of comorbidities and diabetes impacts HbA1c and differs by race. 
Nevertheless, we have the ability to examine the relationship of comorbid conditions and 
exogenous insulin treatment with glycemic control in a race-stratified analysis. 
 
Objectives and Specific Aims 
 The objective of this research is to further our understanding of the psychosocial 
reasons for the large ethnic disparity in diabetes outcomes. African Americans carry a 
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disproportionate amount of the burden of diabetes relative to Caucasian Americans, yet 
the causes of this disparity are not yet fully understood. There have been many successful 
community level interventions, but a large disparity still remains. Understanding critical 
areas for improvement in diabetes care of ethnic minorities can help policymakers and 
health care providers shape the standards of diabetes care to alleviate the burden of 
diabetes on individuals, the U.S. economy and the health care system. Thus, in this study 
we will attempt to assess whether ethnic disparities in self-management behaviors and 
empowerment exist and are associated with glycemic control.  
 One self-management behavior, medication adherence, is a highly promising 
candidate for intervention if it is found to be a source of ethnic disparity in diabetes care, 
because of all the self-management behaviors, it is probably the best determinant of 
glycemic control. It has also been shown to be heavily dependent on patient-provider 
communication. Moreover, studies described above have shown that patient-provider 
communication depends on racial concordance, or lack thereof, between patient and 
physician. However, there is still debate as to whether broader ethnicity-based differences 
in medication adherence exist. This study will evaluate whether or not ethnicity-based 
differences in medication adherence exist and whether medication adherence is 
associated with glycemic control. 
 Additionally, diet and exercise are two related self-management behaviors that 
may also open the door to new promising ethnically tailored diabetes care intervention. 
Obesity rates are higher among African Americans, and obesity is one of the strongest 
risk factors for diabetes onset and progression. This may explain in part the ethnic 
disparity in diabetes outcomes. Culturally appropriate/sensitive/relevant interventions 
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could be designed to improve the dietary practices and activity levels of African 
American patients with diabetes. This study will also assess the relationship between 
ethnicity, diet and exercise, as well as the relationship between diet, exercise and 
glycemic control. 
 The model of care for treatment of type 2 diabetes has shifted from a compliance-
focused and physician-centered model to an empowerment-focused and patient-centered 
model in the last decade and a half. It is important to understand how this model shift 
may differentially impact patients of different ethnicities. Additionally, it is of interest to 
understand whether pre-intervention levels of diabetes-specific empowerment depend on 
race. This study will assess whether ethnic differences in empowerment levels exist and 
whether they are associated with glycemic control. The conceptual model in Figure 1 
depicts the main hypotheses tested in this study, which are outlined below: 
 
1. Poor glycemic control is associated with (a) lower frequency of self-management 
behaviors, (b) lower levels of diabetes-specific empowerment and (c) African 
American ethnicity. 
 
2. The relationship between ethnicity and glycemic control is mediated by self-
management behaviors, such that African American ethnicity is associated with 
poorer diabetes self-management behaviors, and poorer diabetes self-management 
behaviors is associated with higher HbA1c. 
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3. African American ethnicity moderates the relationships of HbA1c with (a) 
diabetes treatment regimen and (b) number of comorbid conditions, such that both 
factors are associated with increased HbA1c for African Americans but not 
Caucasian Americans. 
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Materials and Methods 
 The data analyzed in this study were collected by James E. Aikens, Ph. D.. and 
colleagues at the University of Michigan from 2003-2008 for a study entitled, “Racial 
differences in diabetes-depression comorbidity,” funded by the National Institutes of 
Health. The University of Michigan Institutional Review Board granted Eli Cornblath 
and James Aikens, Ph. D. exemption (HUM00068928) from approval/regulation for a 
secondary analysis on a modified version of this data set lacking patient identifiers. The 
following section describes the methodology by which the data were originally collected 
and the data analytic approach taken for this present. 
 
Participants 
Potential participants were identified using the administrative and clinical 
databases of the Henry Ford Health System in Detroit, Michigan. Patients were eligible if 
they had Type 2 diabetes mellitus, as indicated by at least one of the following: (i) at least 
one hospital admission with a diabetes-related ICD-9 code (250.x, 357.2, 362.0 or 
366.41); (ii) at least two outpatient visits with a diabetes-related ICD-9 code; or (iii) at 
least one prescription for an oral glucose-lowering medication or monitoring supplies. In 
order to be eligible, patients also had to be of either Caucasian or African-American 
ethnicity, able to complete self-report instruments and not diagnosed with bipolar 
depression.  
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Procedures 
Eligible patients were mailed a study invitation letter, followed by a recruitment 
telephone call from research staff (including both African-American and Caucasian 
recruiters) for further screening and enrolment scheduling. After informed consent, 
participants attended a research appointment for assessment of baseline variables 
including diabetes regimen adherence and self-care behaviors, long-term glycemic 
control, empowerment, medical characteristics, and demographic characteristics. All 
procedures were approved by the University of Michigan Institutional Review Board. 
 
Measures 
Medication adherence was assessed using the 4-item measure developed by 
Morisky et al., which elicits information about the presence of various forms of 
medication non-adherence and has demonstrated concurrent and predictive validity and 
adequate internal consistency.49 Additional self-care behaviors (diet, exercise, foot care 
and blood glucose monitoring) were assessed with the Summary of Diabetes Self-Care 
Activities (SDSCA)50, which has adequate test–retest reliability, is sensitive to change 
and is correlated with other measures of the same constructs. Comorbid medical illnesses 
were assessed by abstracting electronic medical records using a checklist of 13 common 
medical illnesses used in prior primary care studies.51,52 Glycemic control (glycated 
haemoglobin; HbA1c) was measured with the DCA 2000 (GMI Inc., Ramsey, MN, 
USA), which analyses capillary blood samples through a monoclonal antibody method. 
Participants classified themselves using U.S. Census racial/ethnic categories. Socio-
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economic status (SES) was assessed using the U.S. Census Bureau Index of Socio- 
economic Status12 adjusted for the current regional Consumer Price Index.  
 
Data analysis 
Descriptive statistics were calculated to summarize study variables. Variables 
with skewed distributions were rank converted for analysis. Bivariate associations were 
conducted to identify potential confounders using Pearson correlation and independent-
samples Student’s t-tests for continuous variables. Associations between HbA1c, self-
management behaviors, ethnicity and various covariates were analyzed using 
multivariable ordinary least-squares (OLS) regression. Independent variables were 
entered in separate blocks corresponding to demographic control covariates, main effects, 
and (when applicable) interaction effects, evaluated against an alpha criterion of p < 0.05. 
All analyses were adjusted for age. 
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Results 
Preliminary analysis of bivariate associations 
 
We conducted a preliminary analysis to identify important factors to take into account 
when subsequently testing for ethnically based disparities in glycemic control. As 
expected, African Americans had significantly higher HbA1c values than Caucasians 
(7.90 ± 1.90 vs. 7.34 ± 1.38, t(286)= -2.765, p=0.006) (Table 1). Interestingly, ethnicity 
was not significantly related to levels of either empowerment (t(281)= -1.082, p=0.280), 
diet (t(283)= -1.681, p=0.094), exercise (t(285)= -0.199, p=0.842), medication adherence 
(t(281)= -0.585, p=0.559), duration of diabetes diagnosis (t(263)= 1.124, p=0.262), or 
SES (t(285)= 0.045, p=0.965) (Table 1). However, several other factors were found to be 
disproportionately prevalent among African Americans. A significantly greater 
proportion of African Americans patients were being treated with exogenous insulin than 
Caucasians (t(283)= -2.154, p= 0.0321). African American individuals had higher 
number of comorbid conditions (t(260)= 4.096, p<0.001 ). Additionally, African 
Americans were significantly younger than Caucasians (59.10 ± 8.75 vs. 54.45 ± 8.16, 
t(283)= 4.625, p<0.001) (Table 1). 
 
All of the ethnicity-associated medical characteristics were also associated with HbA1c. 
A high number of comorbid conditions (b= -0.177, p=0.004) and treatment with 
exogenous insulin (7.446 ± 0.120 vs. 8.021 ± 0.176, t(282)= -2.791, p=0.006) were both 
significantly associated with higher HbA1c and were more prevalent in African 
Americans (Table 2). On the other hand, increasing age was associated with lower 
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HbA1c (b= -0.303, p<0.001), and Caucasians were older than African Americans on 
average. Additionally, men had significantly higher HbA1c than women (7.91 ± 0.15 vs. 
7.37 ± 0.13, t(285)=2.723, p=0.007), although sex was balanced by race (Table 2). This 
preliminary analysis identified several factors associated with the a priori dependent 
variables, which were therefore considered as potential control covariates in subsequent 
multivariable analyses. 
 
Primary data analysis for testing hypotheses: 
 
Hypothesis 1. Poor glycemic control is associated with (a) lower frequency of 
self-management behaviors, (b) lower levels of diabetes-specific 
empowerment and (c) African American ethnicity. 
 
Multiple regression was used to determine the relationship between poor 
glycemic control and diabetes self-management behaviors, diabetes-specific 
empowerment, and African American ethnicity. For all analyses, age was used 
as a control covariate. Although regimen type and comorbid conditions were 
associated with ethnicity and predictive of HbA1c, they were not used as 
control covariates because treatment with exogenous insulin and a high 
number of comorbid conditions are themselves reflective of disparities in 
glycemic control. Additionally, male sex was associated with higher HbA1c, 
but was not included as a control covariate because this association is not 
present in the general population. 
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Test of Hypothesis 1a. For analyses of self-management behaviors, HbA1c was 
the dependent variable, and diabetes self-management behaviors were tested 
individually as the independent variables. The self-management behaviors tested 
were medication adherence, diet and exercise. Lower HbA1c was significantly 
associated with better medication adherence (b = 0.152, p = 0.008). However, 
HbA1c was not associated with diet (b = -0.089, p = 0.122) or exercise (b = -
0.037, p = 0.513) (Table 2). 
 
Test of Hypothesis 1b. To test for a potential relationship between HbA1c and 
diabetes-specific empowerment, HbA1c was used as the dependent variable and 
diabetes-specific empowerment was the independent variable. Higher diabetes-
specific empowerment was significantly was associated with lower HbA1c (b = -
0.216, p < 0.001) (Table 2). 
 
Test of Hypothesis 1c. To test for ethnically based disparities in glycemic control, 
HbA1c was used as the dependent variable and ethnicity was used as the 
independent variable. Although African Americans in this study had worse 
glycemic control overall (Table 1), African American ethnicity was not 
significantly associated with HbA1c in the presence of age as a control covariate 
(b = 0.098, p = 0.095), suggesting that differences in age account for ethnically 
based disparities in HbA1c (Table 3). 
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Hypothesis 2.   
a. The relationship between ethnicity and glycemic control is mediated 
by self-management behaviors, such that African American ethnicity 
is associated with poorer diabetes self-management behaviors, and 
poorer diabetes self-management behaviors is associated with higher 
HbA1c.  
b. The relationship between ethnicity and glycemic control is mediated 
by diabetes-specific empowerment, such that African American 
ethnicity is associated with lower diabetes-specific empowerment, and 
lower diabetes-specific empowerment is associated with higher 
HbA1c.  
 
The results of the test of Hypothesis 1c showed that there was not a 
significant association between ethnicity and HbA1c. Therefore, the 
mediation relationship proposed in Hypothesis 2 was rejected. However, 
we proceeded to test the other associations specified in Hypothesis 2. 
Multiple regression was used to determine the relationship between 
ethnicity and either self-management behaviors (2a) or diabetes-specific 
empowerment (2b).  
 
Test of Hypothesis 2a. For analyses of self-management behaviors, self-
management behaviors (diet, medication adherence, and exercise) were 
individually analyzed as the dependent variable. Ethnicity was used as the 
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primary independent variable. Age was used as a control covariate for 
analyses of diet, exercise and medication adherence. Medication 
adherence was not significantly associated with ethnicity (b = -0.000, p = 
0.999). Diet was significantly associated with ethnicity (b = 0.143, p = 
0.019), with African Americans having better dietary habits than 
Caucasians in this study. Exercise was not associated with ethnicity (b = 
0.011, p = 0.864) (Table 4).  
 
Test of Hypothesis 2b. To test for associations between ethnicity and 
diabetes-specific empowerment, empowerment was used as the dependent 
variable. Ethnicity was used as the independent variable and age was used 
as a control covariate. Diabetes-specific empowerment scores did not 
differ significantly by ethnicity (b = 0.079, p = 0.198) (Table 4). 
 
Hypothesis 3. African American ethnicity moderates the relationships of 
diabetes treatment regimen and number of comorbid conditions with HbA1c, 
such that treatment with exogenous insulin and the presence of comorbid 
conditions lead to increased HbA1c for African Americans but not Caucasian 
Americans. 
a. Multiple regression was conducted separately on data from Caucasian 
American and African American patients to analyze the relationship 
between HbA1c and exogenous insulin and number of comorbid 
conditions. HbA1c was used as the dependent variable, age was used as a 
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control covariate, and either regimen type or number of comorbid 
conditions was used as the independent variable. For whites, treatment 
with exogenous insulin (b = 0.152, p = 0.094) and number of comorbid 
conditions (b = -0.081, p = 0.413) were not significantly associated with 
HbA1c (Table 5). For African Americans, treatment with exogenous 
insulin (b = 0.073, p = 0.341) and number of comorbid conditions (b = -
0.113, p = 0.168) were not significantly associated with HbA1c (Table 5). 
29 
Discussion 
 The main goal of this research project was to gain a better understanding of the 
reasons behind ethnic disparities in Type II diabetes outcomes. Several theories exist that 
attempt to explain this disparity, yet it still remains unclear which factors contribute most 
to the disparity and by what mechanisms. A better understanding of this ethnic disparity 
would help health care professionals and policymakers design programs and practices 
that would help improve diabetes care for African Americans. In this study, three main 
hypotheses about the ethnic disparity were proposed and examined: 1) performance of 
diabetes self-management behaviors (medication adherence, diet, and physical activity) is 
lower among African American patients, which contributes to poor glycemic control, 2) 
patient empowerment is lower among African American individuals, which leads to poor 
diabetes management and worse glycemic control, and 3) treatment with exogenous 
insulin and increased comorbidities would have a larger negative impact on HbA1c for 
African Americans than for Caucasian Americans. Conceptual models outlining the 
hypotheses we developed to examine these theories are presented in Figure 1.  
 In order to test these hypotheses, we studied a group of 250 patients from the 
Henry Ford Health System, half of whom were self-identified as African American / 
Black and the other half as Caucasian American / White. Survey questionnaires were 
administered to collect data on diabetes self-management behaviors, demographic 
information, and social factors, while HbA1c values were obtained for each patient by 
blood testing. The present analysis of these data failed to confirm most of the study 
hypotheses surrounding ethnic disparities. Nevertheless, by indicating the unfruitfulness 
of certain directions, the findings certain might still be helpful in improving healthcare 
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professionals’ understanding of ethnic disparities in diabetes care and ultimately help 
lead to novel interventions aimed at combating these disparities. 
 As expected, better medication adherence and higher diabetes-specific 
empowerment were associated with better glycemic control. Surprisingly, after adjusting 
for age, there was no significant relationship between ethnicity and HbA1c. Also, diet 
and exercise were not related to HbA1c. Thus, our first two hypotheses were not 
supported, as there was no relationship between the outcome variable and the main 
predictor. However, further hypothesis testing was conducted to identify potential 
relationships between ethnicity and mediator variables (self-management behaviors and 
empowerment). These tests showed that medication adherence, diabetes-specific 
empowerment and exercise did not significantly differ by ethnicity. Although diet was 
significantly healthier among African Americans, it was not related to HbA1c. 
Additionally, while treatment with exogenous insulin and a high number of comorbid 
conditions were more prevalent among African American patients and were associated 
with higher HbA1c overall, neither of these factors were associated with HbA1c for 
Caucasians or African Americans after adjusting for age. Overall, that the factors we 
analyzed did not significantly contribute to ethnic disparities in diabetes outcomes; 
nonetheless these results may help redirect efforts to reduce disparities towards other 
factors and lay the foundation for future studies to investigate ethnic disparities in 
different aspects of patient care.  
 Our preliminary analyses showed that there was a significant ethnic disparity in 
glycemic control, with African Americans having higher HbA1c than Caucasian 
Americans. However, after the inclusion of age as a control covariate, we found that 
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ethnicity was not related to glycemic control in our study, which was surprising, given 
that most studies of diabetes patients demonstrate vast ethnic disparities in glycemic 
control even after adjusting for potential confounders. In our sample, age was 
disproportionately represented with respect to race, in that the group of African 
Americans contained a constituent of younger patients, while the group of Caucasian 
Americans lacked younger patients but contained several older patients. In the general 
population, older individuals with diabetes typically have better glycemic control than 
younger individuals.  
This imbalance in age possibly explains why there was a significant relationship 
between ethnicity and Hba1c before accounting for control covariates, but it does not 
explain the lack of disparity after statistical adjustment for patient age. Limitations 
inherent to the study design may explain this lack of association; namely, every patient in 
our sample had private health insurance, which could have acted as an SES “equalizer,” 
masking the effects of African American ethnicity on glycemic control. If every patient 
had easy, affordable access to quality diabetes care, then factors that ordinarily lead to 
disparities may have been resolved. If this were the case, that would provide a very 
interesting insight into the mechanisms of ethnic disparities in diabetes outcomes. For 
example, it may suggest that access to health information and providers, doctor-patient 
communication and SES in general are important determinants of glycemic control for 
African Americans. It would also suggest that genetic differences are an unlikely 
explanation for elevated HbA1c among African Americans, because equal insurance 
would not have overcome any significant genetic component and we would have seen a 
disparity in our sample. This issue will be further discussed in the “Limitations” section. 
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Although this result conflicted with the predictions made by the hypotheses, we 
proceeded with data analysis in order to gain other insights about factors that influence 
glycemic control for all patients, as well as African Americans in particular. 
Our second hypothesis was that medication adherence mediated the relationship 
between ethnicity and HbA1c. While there was no relationship between ethnicity and 
HbA1c in our study, we still analyzed the other aspects of this mediation relationship and 
found that there was an association between medication adherence and glycemic control, 
such that higher medication adherence was associated with better glycemic control. The 
literature largely supports this result, as many studies have shown that medication 
adherence is important for the management of chronic conditions, including diabetes. 
Thus, improving adherence to OHAs and injected insulin regimens remains an important 
target in trying to improve diabetes outcomes for the general population of individuals 
with diabetes. As stated in the introduction, the literature presents conflicting data as to 
whether ethnically based disparities in medication adherence exist. The presence or 
absence of a disparity likely depends on differences in the populations sampled in each of 
these studies. While we hypothesized that medication adherence would be poorer among 
African Americans, adjusted analyses revealed a lack of association between African 
American ethnicity and medication adherence. This finding gives further support to the 
idea that ethnic disparities in medication adherence do not underlie disparities in diabetes 
outcomes. 
In addition to medication adherence, diet and exercise are two other important 
diabetes self-management behaviors. When carried out consistently, healthy diet and 
frequent exercise are considered very effective ways to manage blood sugar levels and 
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are recommended by health care providers before resorting to OHAs. Thus, we 
hypothesized that positive diet and exercise habits were associated with lower blood 
sugar and also performed less frequently by African Americans, serving as a source of 
disparity in glycemic control. Surprisingly, we found that neither diet nor exercise were 
significantly associated with glycemic control. One potential explanation for these results 
is that no patient in the study had a healthy enough diet or frequent enough exercise to 
effectively manage their diabetes, so small improvements in these behaviors did not 
translate to significant changes in HbA1c. Similarly, individuals may have filled out their 
questionnaire based on a “good week,” rather than accurate representation of their overall 
exercise and diet habits. African Americans had significantly better diet habits than 
Caucasian Americans, but this difference is likely not important because of the lack of 
association between diet and HbA1c and the fact that the difference was not large in 
magnitude. We also found no significant difference in exercise habits by race. The lack of 
association with ethnicity did not align with our predictions; however, the homogeneity 
of SES in the sample may also explain this result, especially because diet and exercise are 
so highly correlated with SES. African American cultural dietary practices were 
discussed in the introduction and cited as a potential contributing factor to poor diet 
among African Americans, but it is possible that these cultural practices are not as salient 
among African Americans in the Northern United States as they are in the south and thus 
are largely not relevant to the population we studied. 
Next, we examined associations between diabetes-specific empowerment and 
glycemic control and tested whether empowerment mediated any association between 
race and glycemic control. Although we already found that race was not associated with 
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glycemic control, we nevertheless tested the other associations specified by this 
mediation hypothesis in order to gain further insights into the factors that influence 
glycemic control. These associations were 1) empowerment and glycemic control, and 2) 
race and empowerment. Our results showed that higher levels of diabetes-specific 
empowerment were associated with better glycemic control. This finding provides 
support for the importance of empowerment in a patient’s ability to effectively manage 
their diabetes. Although we looked retrospectively at the association between glycemic 
control and empowerment, this positive association nevertheless affirms the idea that 
empowerment-based treatment programs are promising candidates to improve diabetes 
self-management for patients regardless of race. Almost no quantitative studies have 
simultaneously analyzed and compared diabetes-specific empowerment, self-efficacy or 
other similar constructs for both African Americans and Caucasian Americans, but those 
studies that have showed no significant racial differences in baseline scores. However, a 
review of the qualitative literature led us to hypothesize that empowerment would be 
lower among African Americans and be a large driving factor of ethnic disparities in 
glycemic control. Contrary to the predictions we made prior to analysis, we did not find a 
significant association between empowerment and ethnicity; thus, this study supports the 
lack of an ethnic disparity in baseline empowerment scores. However, it is also possible 
that in our sample, African Americans had higher levels of empowerment than in a 
population without HAP insurance.  
 Our last hypothesis was designed to understand ethnic disparities in diabetes 
outcomes, as opposed to disparities in self-management behaviors. We predicted that the 
HbA1c was associated with treatment with exogenous insulin and comorbidities in a 
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race-dependent fashion, such that the presence of comorbid conditions and treatment with 
exogenous insulin among African Americans leads to higher HbA1c, moreso than for 
Caucasian Americans, if at all. After stratifying the data by ethnicity, we found that for 
both races, there was no association between HbA1c and treatment with exogenous 
insulin or number of comorbid conditions. Our data was not well suited to perform this 
analysis, which may limit our ability to interpret our results. Because we did not follow 
these patients longitudinally from their initial diabetes diagnosis, we could not monitor 
the development of comorbid conditions in relation to changes in HbA1c. Additionally, 
while we recorded whether patients were being treated with exogenous insulin at the time 
of the study, we did not obtain data about the time at which they began that treatment 
regimen, which may be a confounding factor in this analysis. 
 
Limitations 
There were several limitations inherent to the study design that may have 
influenced the interpretation of the data. One of the most global issues with our study was 
the fact that we relied heavily on self-report survey data. While biological measures such 
as HbA1c, BMI, and sex were included, a majority of the data was collected via 
questionnaires that the patients were allowed to fill out on their own. Self-report data has 
limited reliability for a variety of reasons. Lenzner et al. describe several elements of 
survey design, such as difficult vocabulary, complicated syntax and poor clarity, which 
can increase the burden of responding and lead to inaccurate data.53 More specifically, 
self-report was among the least valid methods available to measure medication 
adherence.29 Better-validated methods for measuring adherence include pill counts and 
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collateral reports, because these methods veer closer towards direct observation than self-
report. Crowne and Marlowe (1964) introduced the theory that study participants respond 
to surveys in a way that presents themselves as more socially desirable.54 In our study, 
this may translate into patients overestimating their medication adherence, diet and 
exercise. But although our data relies on self-report, the scales we used have been 
reasonably well-validated. For example, the Morisky Scale of Medication Adherence is 
used in many studies and has demonstrated high validity. Morisky et al., the group that 
developed the scale, conducted a study in 1986 of patients being treated with 
antihypertensive medications, demonstrating that Morisky scores were significantly 
correlated with blood pressure control.49 Additionally, they conducted a similar study 
testing both the 4-item scale a modified 8-item scale (not used in this thesis) in 2008, 
again showing that adherence scores were correlated with control of blood pressure.55  
One of the major limitations mentioned above was the underrepresentation of 
individuals with lower SES. Part of the selection process for this study was to find 
individuals with private insurance from the Michigan Health Alliance Plan (HAP). Thus, 
health care access did not vary widely in our sample. Also, income and education levels 
were relatively homogeneous within our sample as well. This bias may have skewed our 
data our masked disparities that were largely due to race-related disparities in SES. 
Large-scale studies have reported significantly increased prevalence of diabetes among 
lower SES populations56 and have shown that diabetes is more poorly controlled in lower 
SES individuals57, but our study failed to find an association between SES and HbA1c, 
likely due to the fact that SES was homogeneous in our study. This lack of association 
prevented us from analyzing the interaction between SES and race or other factors. 
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Nevertheless, we had enough of a representative range for factors like medication 
adherence and empowerment that allowed us to identify important associations 
regardless. 
Another limitation was the lack of data on physician race and a lack of minority 
physicians. There was only a small number of physicians whom patients identified as 
non-Caucasian (n = 6), which was insufficient for any analysis of the role that racial 
discordance might play in diabetes care. Additionally, because data on the race of the 
physician was collected by patient self-report, the races reported may not align with how 
the physicians would identify their own race. Obtaining further data on the race of the 
physician treating each patient would greatly enhance our ability to ask the important 
question of whether racial concordance influences the quality of diabetes care. Because 
we did not find any factors that were significant predictors of ethnic disparity in glycemic 
control and diabetes care, it would have been interesting to explore doctor-patient 
communication as a potential reason. A 2008 survey by the Center for Studying Health 
System Change found that 73.7% of physicians identified as non-Hispanic White, while 
only 3.8% of physicians identified as non-Hispanic Black36, which is consistent with the 
lack of minority physicians in our study without intentional recruitment. It may have been 
necessary to design the study so that the sample was balanced with respect to each 
combination of patient race and physician race, i.e. Caucasian patients with African 
American physicians, Caucasian patients with Caucasian physicians, African American 
patients with Caucasian physicians, and African American patients with African 
American physicians. Moreover, additional survey questionnaires could have been added 
to assess how these patients perceived the communication. However, the existing tools 
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for measuring the extent to which a patient feels that a physician has communicated 
effectively and provided patient-centered care are limited in their consistency and 
reliability.58,59  
 Finally, our heavy reliance on quantitative data may have oversimplified and 
masked phenomena that explain the ethnic disparity in diabetes outcomes. Inclusion of 
in-depth, qualitative interviews could have helped capture the deeper, more personal 
aspects of diabetes care and would have allowed us to triangulate our findings. 
Qualitative interview data would have particularly provided us with a richer perspective 
on each patient’s experience communicating with health care professionals and how that 
impacted their ability to manage their diabetes. It would also give us more insights about 
the implications of holding an African American racial identity in a medical setting, both 
for physicians and patients, which is important for a field that has historically been 
dominated by Caucasian American males.36 
 
Implications 
 Type 2 Diabetes Mellitus is one of the most common chronic diseases, afflicting 
8% of the US population. Prevalence of diabetes has increased greatly over the last 50 
years, and even the last 10, generating an enormous social, economic and medical burden 
on the US. Thus, it is an urgent medical concern to help reduce the development of and 
treat diabetes. The burden of diabetes is not shared equally among the US population; 
African American individuals comprise a disproportionate amount of individuals with 
diabetes and experience more diabetes-related complications that individuals with 
diabetes of other ethnic backgrounds. This thesis presents an overview of research aimed 
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at identifying the reasons behind ethnic disparities in diabetes, with a focus on 
psychosocial and behavioral explanations, followed by novel research on how ethnicity, 
medication adherence, patient empowerment and treatment regimens relate to 
management of chronic hyperglycemia.  
The findings in this study point towards several potential actions that can be taken 
to both improve the ethnic disparity and further understand it. While this study did not 
directly identify factors that differed by race and were associated with glycemic control, 
it still reaffirmed current perspectives on diabetes treatment and highlights the need for 
further studies on diabetes in African Americans. Diabetes-specific empowerment was 
associated with better glycemic control, which provides support for the continuation and 
expansion of the empowerment approach to diabetes care. This study compared baseline 
levels of empowerment between African American and Caucasian American individuals 
and showed that they were equal, a comparison that has rarely been made in the 
literature. While the empowerment approach has been shown to be successful among 
African Americans, it may not be a specific way to address the ethnic disparities in 
diabetes outcomes. Moreover, it is important to thoroughly examine how the 
empowerment-based approach might differentially impact Caucasian and African 
American patients when implemented on a larger scale with a more diverse patient 
population. The effectiveness of empowerment-based programs may differ by SES, 
occupation, personality type, education levels, various lifestyle differences, and more. 
Health care providers could begin to adopt empowerment-based programs as their 
standard protocol for diabetes treatments and the government could create financial 
incentives for institutions that instate these programs. If an increased number of 
40 
empowerment-based programs could effectively reduce the economic burden of diabetes, 
then the financial incentive would be reason enough alone to include empowerment-
based programs in diabetes treatment. 
Medication adherence was also associated with better glycemic control. Although 
the empowerment model deemphasizes the concept of “adherence,” this finding 
nevertheless supports the idea that taking medications as prescribed does lead to better 
glycemic control. Interestingly, medication adherence did not differ by race, which may 
suggest that ethnic disparities do not manifest themselves through disparities in 
medication adherence. Similarly, improving medication adherence will also likely 
improve diabetes management, but as Anderson and others have suggested, an 
adherence-centered model of diabetes care may not be effective. 
Although this study did not examine any physiological or genetic data, our results 
point towards a need for more biological research related to ethnic disparities in diabetes. 
Diet and exercise were not associated with HbA1c, although African Americans reported 
slightly healthier diet than Caucasians. Biological studies could be done to identify ethnic 
differences in metabolism and response to improvements in diet and physical activity 
levels. Moreover, if the behavioral and psychosocial factors related to glycemic control 
truly did not differ by ethnicity, then genetic differences may indeed play a role in this 
disparity. Further research into potential genetic factors responsible for increased risk for 
Type 2 diabetes and increased rates of diabetes-related complications among African 
Americans could lead to the development of new medications and other treatments to 
more effectively compensate for these differences.   
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These results could also inform the design of a randomized controlled trial to 
investigate the role of other factors in ethnic disparities in diabetes care. Our lack of 
variation in SES underscores the importance of having a wide representation of SES 
levels in subsequent studies. Ethnicity may interact with SES in ways that we could not 
assess in our data, and this analysis should be conducted before investigating other 
perspectives. One important factor that remains to be investigated is the role of doctor-
patient communication. It would be useful to narrow down the focus from medication 
adherence and empowerment to the factors that directly influence an individual’s ability 
to take medicine as prescribed, and the extent to which African American patients 
become empowered. Communication with health care providers plays a large role in 
improving patient empowerment and in promoting medication adherence. Lack of racial 
concordance can have a negative impact on patient physician communication and 
subsequent medication adherence35; thus, a randomized controlled trial could be designed 
to more directly examine how the African American racial identity of patient can affect 
how they are perceived and treated in a health care setting. Studies such as these would 
be helpful in educating physicians and other health care providers to have more 
successful encounters with patients from diverse populations.  
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Figure 1. Conceptual models of main hypotheses. 
 
Hypotheses 1 and 2: 
 
 
 
 
 
 
 
 
 
 
Hypothesis 3: 
Ethnicity HbA1c 
Self-management 
behaviors 
Diabetes-specific 
empowerment 
Ethnicity 
Exogenous insulin 
Comorbidities 
HbA1c 
Table 1. Patient demographics and baseline medical characteristics. 
     
    
Variable  
Total sample 
(n=288) 
White 
(n=124) 
Black 
(n=164) p value 
     
Age, mean ± SD 56.47 ± 8.72  59.10 ± 8.75 54.45 ± 8.16 <0.001 
     
Female, %  48.08 48.38 47.85 0.929 
     
Black, % 57.09 NA NA NA 
     
Insulin and oral meds, % 39.65 32.52 45.06 0.032 
     
Diabetes durationi, mean ± SD 10.73 ± 7.95 11.36 ± 9.42 10.25 ± 6.62 0.262 
     
SESii, mean ± SD 64.83 ± 17.74 64.89 ± 17.33 64.80 ± 18.10 0.965 
     
HbA1c, mean ± SD 7.66 ± 1.72 7.34 ± 1.38 7.90 ± 1.90 0.006 
     
Medication adherenceiii, mean± 
SD 4.80 ± 1.01 4.76 ± 0.93 4.83 ± 1.08 0.559 
     
Empowermentiv, mean ± SD 3.69 ± 0.69 3.63 ± 0.71 3.72 ± 0.67 0.280 
     
Comorbid conditionsv, mean + 
SD 0.79 ± 0.93 1.04 ± 1.04 0.58 ± 0.77 <0.001 
     
Diet, mean ± SD 3.69 ± 1.62 3.51 ± 1.76 3.83 ± 1.49 0.094 
     
Exercise, mean ± SD 2.20 ± 1.95 2.18 ± 2.06 2.22 ± 1.88 0.842 
 
                                                
i Total n=265, White n=114, Black n=151. 
ii Hollingshead SES Index. 
iii Morisky Medication Adherence Scale49. Scores range from 4 to 8, higher score 
indicates poorer medication adherence. 
iv Diabetes Empowerment Scale42. Scale of diabetes-related psychosocial self-efficacy. 
                                                
v Based on self-reported hypertension, cardiovascular disease, hyperlipidemia, cancer, 
stroke, arthritis, chronic lung disease, migraine, asthma, and low back pain. Total 
n=262, White n=118, Black n=144. 
Table 2. Table of bivariate associations between outcome variable and potential 
control covariates. 
    
    
Potential control covariate HbA1ci p value 
   
Age -0.303  <0.001 
   
Diabetes durationii 0.042 0.494 
   
SESiii -0.032 0.589 
   
Medication adherenceiv 0.203 0.001 
   
Empowermentv -0.240 <0.001 
   
Comorbid conditionsvi  -0.177 0.004 
   
Diet -0.145 0.014 
   
Exercise -0.062 0.296 
   
OHA only – Insulin and OHA, 
mean difference ± SD -0.575 ± 0.206 0.006 
   
Male - Female, mean difference ± 
SD 0.544 ± 0.200 0.007 
   
White - Black, mean difference ± 
SD -0.559 ± 0.202 0.006 
 
                                                
i Pearson correlation is reported in this column unless otherwise specified in “Potential 
Control Covariate” column. 
ii Total n=265, White n=114, Black n=151. 
iii Hollingshead SES Index. 
iv Morisky Medication Adherence Scale49. Scores range from 4 to 8, higher score 
indicates poorer medication adherence. 
                                                
v Diabetes Empowerment Scale42. 
vi Based on self-reported hypertension, cardiovascular disease, hyperlipidemia, cancer, 
stroke, arthritis, chronic lung disease, migraine, asthma, and low back pain. Total 
n=262, White n=118, Black n=144. 
  
 
 
 
 
 
 
 
 
 
 
Table 3. Multivariable OLS regression analyses of HbA1c. 
     
    
Dependent Variable  Independent Variables Standard β  p value 
    
n= 285 Age -0.277 <0.001 
R2 total= 0.100 Ethnicityi 0.098 0.095 
P < 0.001    
    
n= 280 Age -0.307 <0.001 
R2 total= 0.132 Medication Adherenceii 0.152 0.008 
P < 0.001    
    
n= 282 Age -0.291 <0.001 
R2 total= 0.0946 Diet -0.089 0.122 
P < 0.001    
    
n= 280 Age -0.304 <0.001 
R2 total= 0.0948 Exercise -0.037 0.513 
P < 0.001    
    
n= 280 Age -0.300 <0.001 
R2 total= 0.146 Empowerment -0.216 <0.001 
P < 0.001    
                                                
i Coded 0 for white, 1 for African American. 
ii Morisky medication adherence scale49. Higher scores indicate lower adherence. 
Table 4. Multivariable regression analyses of self-management behaviors 
and empowerment. 
     
    
Dependent Variable  Independent Variables 
Standard 
β  p value 
    
Medication Adherence Age -0.155 0.012 
n= 280 Ethnicityi -0.000 0.999 
R2 total= 0.024    
P = 0.034    
    
Diet Age 0.198 0.001 
n= 282 Ethnicity 0.143 0.019 
R2 total= 0.044    
P = 0.002    
    
Exercise Age 0.045 0.468 
n= 284 Ethnicity 0.011 0.864 
R2 total= 0.002    
P = 0.768    
    
Empowerment Age 0.088 0.154 
n= 280 Ethnicity 0.079 0.198 
R2 total= 0.011    
P = 0.225    
    
 
                                                
i Coded 0 for white, 1 for African American. 
Table 5. Multivariable regression analyses of HbA1c on regimen type by ethnicity. 
     
    
Ethnicity Independent Variables Standard β  p value 
    
White Age -0.190 0.037 
n= 123 Regimen Typei 0.152 0.094 
R2 total= 0.050    
P = 0.046    
    
African American Age -0.349 <0.001 
n= 158 Regimen Type 0.073 0.341 
R2 total= 0.138    
P < 0.001    
    
White Age -0.141 0.157 
n= 118 Comorbid Conditions -0.081 0.413 
R2 total= 0.035    
P = 0.127    
    
African American Age -0.293 <0.001 
n= 140 Comorbid Conditions -0.113 0.168 
R2 total= 0.109    
P < 0.001    
 
                                                
i Coded 0 for OHAs only, 1 for OHAs and exogenous insulin. 
